Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)

SHA:688076 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	1,833	1,623	1,033	648.03	641.71	564.99
Other Revenue	1.99	1.99	0.82	3.26	2.16	1.89
Revenue	1,835	1,625	1,034	651.29	643.87	566.87
Revenue Growth (YoY)	55.30%	57.21%	58.69%	1.15%	13.58%	52.58%
Cost of Revenue	627.1	575.05	444.27	307.94	306.3	249.55
Gross Profit	1,207	1,050	589.28	343.36	337.57	317.32
Selling, General & Admin	374.26	339.13	268.23	186.98	150.49	120
Research & Development	239.67	227.45	124.89	69.47	63.09	60.53
Other Operating Expenses	5.32	1.7	0.02	9.25	5.24	3.65
Operating Expenses	633.37	588.89	398.25	271.58	220.47	185.87
Operating Income	574.12	460.86	191.04	71.78	117.1	131.45
Interest Expense	-41.3	-34.75	-16.09	-9.26	-6.12	-11.63
Interest & Investment Income	10.17	9.05	9.11	28.54	8.38	7.16
Currency Exchange Gain (Loss)	8.68	8.68	-1.38	1.03	-1.58	-7.73
Other Non Operating Income (Expenses)	0.67	-0.58	-0.47	-0.3	-0	-1.12
EBT Excluding Unusual Items	552.34	443.26	182.22	91.79	117.78	118.14
Impairment of Goodwill	-	-	-	-	-1.28	-
Gain (Loss) on Sale of Investments	-2.79	-2.79	0.26	-1.96	0.13	-
Gain (Loss) on Sale of Assets	-9.47	-9.2	-15.06	18.44	-0.97	-4.12
Asset Writedown	-12.76	-	-	-	-	-
Other Unusual Items	8.08	7.24	5.71	14.9	10.07	32.55
Pretax Income	535.4	438.5	173.13	123.16	125.73	146.56
Income Tax Expense	52.27	38.69	7.67	0.39	16.92	26.53
Earnings From Continuing Operations	483.13	399.82	165.45	122.77	108.81	120.03
Minority Interest in Earnings	7.55	4.57	-2.52	6.34	6.58	3.41
Net Income	490.68	404.39	162.94	129.11	115.39	123.44
Net Income to Common	490.68	404.39	162.94	129.11	115.39	123.44
Net Income Growth	135.62%	148.19%	26.20%	11.89%	-6.52%	153.94%
Shares Outstanding (Basic)	304	301	300	296	269	224
Shares Outstanding (Diluted)	309	308	300	296	269	224
Shares Change (YoY)	1.63%	2.52%	1.28%	10.06%	19.95%	-1.06%
EPS (Basic)	1.62	1.34	0.54	0.44	0.43	0.55
EPS (Diluted)	1.59	1.31	0.54	0.44	0.43	0.55
EPS Growth	131.85%	142.09%	24.60%	1.66%	-22.07%	156.65%
Free Cash Flow	-809.03	-690.01	-310.43	-409.07	-52.61	30.1
Free Cash Flow Per Share	-2.62	-2.24	-1.03	-1.38	-0.20	0.13
Dividend Per Share	0.643	0.643	0.286	0.143	0.107	-
Dividend Growth	125.03%	125.03%	99.93%	33.43%	-	-
Gross Margin	65.82%	64.61%	57.02%	52.72%	52.43%	55.98%
Operating Margin	31.29%	28.36%	18.48%	11.02%	18.19%	23.19%
Profit Margin	26.75%	24.89%	15.77%	19.82%	17.92%	21.78%
Free Cash Flow Margin	-44.10%	-42.47%	-30.04%	-62.81%	-8.17%	5.31%
EBITDA	793.53	662.75	322.81	170.52	198.73	202.16
EBITDA Margin	43.25%	40.79%	31.23%	26.18%	30.87%	35.66%
D&A For EBITDA	219.41	201.88	131.77	98.75	81.63	70.71
EBIT	574.12	460.86	191.04	71.78	117.1	131.45
EBIT Margin	31.29%	28.36%	18.48%	11.02%	18.19%	23.19%
Effective Tax Rate	9.76%	8.82%	4.43%	0.32%	13.46%	18.10%
Revenue as Reported	1,835	1,625	1,034	651.29	643.87	566.87

Source: S&P Global Market Intelligence. Standard template. Financial Sources.